BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

The headline news in the new agreement is the formation of a joint AI Innovation Lab – split between InstaDeep’s headquarters in London in the UK and BioNTech’s site in Mainz Germany ...

Germany's foreign intelligence service in 2020 put at 80%-90% the likelihood that the coronavirus behind the COVID-19 ...

BioNTech, based in the western German city of Mainz, reported net profits in 2023 of €930.3 million ($1.01 billion) on Wednesday. That was a major drop from the €9.4 billion in profits the ...

Penn will receive $467 million under a settlement with German drug manufacturer BioNTech, which partnered with Pfizer to develop a COVID vaccine that relied on mRNA technology developed at the ...

In the last three months, 4 analysts have published ratings on BioNTech BNTX, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their ...

German biotech firm BioNTech reported a loss of €665.3 million ($721 million) in 2024, as demand for its COVID-19 vaccines fell, according to the company's financial results report on Monday.

BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.

BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.